EMA RELEASES REVISED GUIDANCE TO FIGHT EARLY ONSET ALZHEIMER’S DISEASE
February 1st, 2016
THE EUROPEAN Medicines Agency (EMA) has released draft revised guidance on the development of medicines treating Alzheimer’s disease, with the aim of helping pharmacos produce treatment targeting the disease’s early onset. EMA is responding to research suggesting that biological changes associated with the disease start to occur as early as 10 to 20 years prior to clinical symptoms. “Experimental medicines should therefore be evaluated in earlier disease stages as certain treatments may be more effective at that stage than later in the illness,” said an ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.